Left Atrial Appendage Exclusion (LAAE) is recommended during heart surgery by The Society of Thoracic Surgeons, American College of Cardiology, and the American Heart Association
Interested in having some hands-on experience? Visit booth #1035 to get hands-on with the EPi-Sense ST™ Device using our simulation model.
The EPi-Sense System is the first and only FDA approved minimally invasive ablation therapy for Advanced Afib patients.
Learn more:… https://t.co/0UKpZ7IZCS
Live from #HRS2024! Dr. Oza shared data from his latest paper on the impact of hybrid ablations in patients with Afib and heart failure. Listen in to hear what the data means for patients and treaters. #Epeeps#CardioTwitter
Welcome to #HRS2024! Come stop by Booth #1035 this weekend to connect with our team of experts to learn more about the Hybrid Convergent procedure, the benefits of LAA exclusion, now a class 1A recommendation by all major societies, and get hands-on with our simulation model.
HRS joins the movement, classifying LAAE as a Class 1A recommendation.
With over 20 years of innovation, AtriClip® is the device leader in LAA exclusions.
Discover more at booth #1035 at #HRS2024 or visit: https://t.co/8BNwZ2BhCc
During Hospital Week, we express our heartfelt gratitude to all the dedicated healthcare professionals who work tirelessly to provide exceptional care to patients every day.
Your unwavering commitment and compassion make a difference in the lives of countless individuals and families. Thank you for your resilience, courage, and unwavering dedication to healing and serving others.
#HospitalWeek
As we celebrate Women’s Health Week, we’re shining a light on IST, a condition that disproportionately affects young women. Symptoms such as a high resting heart rate, chest palpitations, lightheadedness, and anxiety can impact daily life. It's crucial for women to prioritize their health with regular check-ups and to speak up when symptoms arise.
At AtriCure, we're dedicated to advancing patient health. That's why we're proud to be running a new clinical trial, evaluating an innovative treatment option for symptomatic IST. Learn more about the trial: https://okt.to/uXp8DS
#WomensHealthWeek#ClinicalTrial#IST
We’re wishing all moms a Happy Mother's Day! Your love and sacrifices are immeasurable. Today, let's also acknowledge the importance of self-care. Remember, you can't pour from an empty cup. Take time to recharge, prioritize your health, and nurture your well-being. Here's to filling our cups with love and joy! #MothersDay#HappyMothersDay
We celebrate our employees at All Employee Meetings with the Heart of AtriCure Award. This award is one way we recognize employees who embody our values while demonstrating exceptional performance on behalf of each other, our patients and our partners. Congratulations to our recipients Paige Dwyer, Drew Mason, Deb Feldhaus, Amavi Kekeh and Gina Martin!
Today we’re also honoring Terrie Holahan, whose passing has been felt deeply across the AtriCure family. Terrie has been an integral part of AtriCure for over 20 years and her memory will live on with us.
#HeartofAtriCure#AEM#values#employeerecognition
Interested in having some hands-on experience? Visit booth #1035 to get hands-on with the EPi-Sense ST™ and AtriClip® devices using our simulation model.
Left Atrial Appendage Exclusion is a Class 1A recommendation by all major societies. The EPi-Sense System is the first and only FDA approved minimally invasive ablation therapy for Advanced Afib patients.
Learn more: https://okt.to/b8293t
Live from #HRS2024! Dr. Oza shared data from his latest paper on the impact of hybrid ablations in patients with Afib and heart failure. Listen in to hear what the data means for patients and treaters.
#EPeeps#cardiacsurgery
Welcome to #HRS2024! Come stop by Booth #1035 this weekend to connect with our team of experts to learn how you could achieve long-term Afib burden reduction in Advanced Afib patients with the Hybrid Convergent procedure, the benefits of LAA exclusion, now a class 1A recommendation by all major societies, and get hands-on with our simulation model.
HRS is the most recent society to join the growing change in classifying left atrial appendage exclusion as a Class 1A recommendation.
With over 20 years of innovation, AtriClip® is the device leader in LAA exclusions.
To learn more about AtriClip, stop by our booth #1035 at #HRS2024 or visit: https://okt.to/hEIWKG
social media channels to keep updated on the latest at AtriCure.
Blake's Pectus Excavatum Journey: 2 Months Post-Op
Duration: 2:31
Blake's Pectus Excavatum Journey: Surgery
Duration: 2:49
Blake's Pectus Excavatum Journey: 1 Week Pre-Op
Duration: 3:41
Blake's Pectus Excavatum Journey: 1 Month Pre-Op
Duration: 2:58